Altimmune公布MASH新药数据,投资者反应冷淡

Minhua笔记
Yesterday

12月19日,Altimmune宣布IMPACT Phase 2b试验48周顶线结果,pemvidutide(GLP-1/glucagon双激动剂)在非侵入性纤维化标志物(如ELF评分、肝硬度测量)、肝脂肪含量和体重减轻上显著优于安慰剂,继续从24周改善。尽管公司积极宣传,开盘后不久便下跌超过25%,投资者对数据强度和竞争格局失望(此前24周纤维化终点未达到)。Altimmune表示,其在研药物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10